Related Experiment Video
Updated: Mar 15, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA)
Peter Revill1, Stephen Locarnini1
1Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute of Infection and Immunity, Melbourne, 3000, Victoria, Australia.
Insights
Chronic hepatitis B virus (HBV) infection affects 240 million globally, with cures hindered by the persistent viral cccDNA reservoir. Research focuses on eliminating or inactivating this reservoir for a functional or complete HBV cure.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis B virus (HBV) remains a significant global health burden, causing chronic infection in 240 million people and up to 800,000 deaths annually.
- Current antiviral therapies effectively suppress HBV replication but fail to eradicate the transcriptionally active covalently closed circular DNA (cccDNA) nuclear reservoir, preventing a complete cure.
Purpose of the Study:
- To review recent advancements in strategies aimed at eliminating or inactivating the HBV cccDNA reservoir.
- To explore future research directions for achieving a functional or complete cure for chronic hepatitis B.
Main Methods:
- This review synthesizes findings from recent scientific literature.
- It focuses on studies investigating novel approaches to target HBV cccDNA.
Main Results:
- Significant progress has been made in understanding HBV cccDNA biology and developing therapeutic strategies.
- Emerging approaches show promise in either eliminating or functionally inactivating the cccDNA reservoir.
Conclusions:
- Targeting the HBV cccDNA reservoir is crucial for achieving a cure for chronic hepatitis B.
- Continued research into novel elimination and regulation mechanisms is essential to overcome this persistent viral reservoir.
Abstract:
It has been over 50 years since the discovery of hepatitis B virus (HBV), yet 240 million people worldwide live with chronic HBV, resulting in up to 800000 deaths per year. A cure is yet to be achieved, due largely to a viral nuclear reservoir of transcriptionally active covalently closed circular DNA (cccDNA). While current antiviral therapies are effective at reducing viral replication, they have no impact on the existing cccDNA reservoir. Identifying mechanisms to either eliminate (complete cure) or inactivate (functional cure) HBV cccDNA are a major focus of HBV research worldwide. This review discusses recent advances in efforts to eliminate and/or regulate cccDNA, as well as future directions that may be considered in efforts to cure chronic HBV.
Related Concept Videos
Viruses with RNA Genomes
Retrovirus Life Cycles
Size and Structure of Viral Genomes
DNA Bacteriophages
Subviral Agents
The Antiviral System of Bacteria and Archaea: CRISPR

